| 2026-09-14 |
Definium Therapeutics US, Inc. |
Results Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder definiumtx.com ↗
Panorama met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12. |
| 2026-09-08 |
Definium Therapeutics US, Inc. |
Regulatory Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results definiumtx.com ↗
|
| 2026-08-12 |
Definium Therapeutics US, Inc. |
Results Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder definiumtx.com ↗
|
| 2026-06-22 |
Definium Therapeutics US, Inc. |
Results Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder definiumtx.com ↗
Emerge met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in MADRS total score at week 6. |
| 2025-09-04 |
Definium Therapeutics US, Inc. |
Results Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD) definiumtx.com ↗
|
| 2024-12-11 |
Definium Therapeutics US, Inc. |
Results MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress definiumtx.com ↗
today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder |
| 2024-12-05 |
Definium Therapeutics US, Inc. |
Regulatory MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) definiumtx.com ↗
|
| 2024-05-04 |
Definium Therapeutics US, Inc. |
Results MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York definiumtx.com ↗
MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. |
| 2024-03-07 |
Definium Therapeutics US, Inc. |
Regulatory MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder definiumtx.com ↗
|